Achilles Therapeutics Added to the NASDAQ Biotechnology Index
21 December 2021 - 12:00AM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today announced that the Company has been added
to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to
market open today, Monday, December 20, 2021.
The NASDAQ Biotechnology Index is designed to
track the performance of a set of securities listed on The Nasdaq
Stock Market® (Nasdaq®) that are classified as either biotechnology
or pharmaceutical according to the Industry Classification
Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under
a modified capitalization-weighted methodology. Companies in the
NASDAQ Biotechnology Index must meet eligibility requirements,
including minimum market capitalization, average daily trading
volume and seasoning as a public company, among other criteria.
NASDAQ selects constituents once annually in December.For more
information about the NASDAQ Biotechnology Index, please visit
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
unresectable locally advanced and metastatic non-small cell lung
cancer (NSCLC) and the THETIS trial in patients with recurrent or
metastatic melanoma. Achilles uses DNA sequencing data from each
patient, together with its proprietary PELEUS™ bioinformatics
platform, to identify clonal neoantigens specific to that patient,
and then develop precision T cell-based product candidates
specifically targeting those clonal neoantigens.
Forward-Looking StatementsThis
press release contains express or implied forward-looking
statements that are based on our management's belief and
assumptions and on information currently available to our
management. Although we believe that the expectations reflected in
these forward-looking statements are reasonable, these statements
relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Further information:
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Apr 2023 to Apr 2024